On Tuesday, Shares of Target Corporation (NYSE:TGT), lost -0.56% to $77.92.
Target Corporation (TGT), stated first quarter 2015 adjusted earnings per share from ongoing operations1 (Adjusted EPS) of $1.10, up 19.6 percent from $0.92 in 2014. GAAP EPS from ongoing operations were $1.01, contrast with $0.89 in first quarter 2014. First quarter 2015 GAAP EPS from ongoing operations reflect $103 million of restructuring costs that are excluded from Adjusted EPS..
Target Corporation operates as a general merchandise retailer in the United States and Canada. It offers household essentials, counting pharmacy, beauty, personal care, baby care, cleaning, and paper products; music, movies, books, computer software, sporting goods, and toys; electronics, such as video game hardware and software; and apparel for women, men, boys, girls, toddlers, infants, and newborns, in addition to intimate apparel, jewelry, accessories, and shoes.
Shares of Danaher Corporation(NYSE:DHR), declined -0.88% to $86.49. during its last trading session.
Danaher Corporation (DHR) declared that its Board of Directors has approved a regular quarterly dividend of $0.135 per share payable on July 31, 2015 to holders of record on June 26, 2015.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
At the end of Tuesday’s trade, Shares of EXACT Sciences Corporation (NASDAQ:EXAS), gained 4.69% to $25.44.
EXACT Sciences Corporation, declared that data supporting its stool DNA (sDNA) screening platform for colorectal cancer and other screening techniques for the detection of additional gastrointestinal cancers and diseases will be presented in five posters at Digestive Disease Week (DDW) 2015, taking place May 16-19 in Washington D.C. Recently approved by the U.S. Food and Drug Administration (FDA), Exact Sciences’ noninvasive screening test Cologuard® uses sDNA technology to assist detect the presence of colorectal cancer and precancer. Exact Sciences’ technologies can be seen at the show at booth #1552.
“Building on the publication of strong clinical data supporting sDNA technology, followed by the FDA approval of Cologuard, we are happy to see new clinical evidence backing this important screening option at this year’s DDW conference,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Studies like these will continue to drive awareness and adoption of Cologuard and provides Exact Sciences with the preliminary data needed to advance our product pipeline.”
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.
Finally, Unilever N.V. (ADR)(NYSE:UN), ended its last trade with 0.60% gain, and closed at $43.68.
Unilever N.V. (ADR)(NYSE:UN),
First quarter highlights
- Turnover raised 12.3% to EUR 12.8 billion counting a positive currency impact of 10.6%
- Underlying sales growth at 2.8% with emerging markets up 5.4%
- Underlying volume growth at 0.9% and pricing up 1.9%
- Quarterly dividend up 6% to EUR 0.302
Unilever N.V. operates as a fast-moving consumer goods company in the Americas, Europe, Asia, Australasia, Africa, the Middle East, Turkey, Russia, Ukraine, and Belarus. The company operates through Personal Care, Foods, Refreshment, and Home Care segments. The Personal Care segment offers skincare and haircare products, deodorants, and oral care products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
